[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
December 15, 1999

Cholinergic Markers in Alzheimer Disease

Author Affiliations
 

Phil B.FontanarosaMD, Interim CoeditorIndividualAuthorMargaret A.WinkerMD, Deputy EditorIndividualAuthorStephenLurieMD PhD, Fishbein FellowIndividualAuthor

JAMA. 1999;282(23):2208-2209. doi:10-1001/pubs.JAMA-ISSN-0098-7484-282-23-jbk1215

To the Editor: It has been nearly 20 years since the inception and integration of the cholinergic hypothesis,1 the only approach that has so far produced drugs approved for treating Alzheimer disease (AD). The study by Dr Davis and colleagues2 is the first attempt to explore the temporal relationship between progressive declines in key cholinergic markers and memory in AD. The authors report that choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) activities remain normal until the late stages of AD and suggest that the link between cholinergic dysfunction and the onset of the characteristic symptoms is therefore weak. However, caution must be exercised when interpreting data using ChAT and AChE as markers of cholinergic function.

First Page Preview View Large
First page PDF preview
First page PDF preview
×